Canadian Cancer Trials Group
Clinical trials sponsored by Canadian Cancer Trials Group, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immunotherapy drug durvalumab tested to stop bladder cancer return Results expected Oct 2026 (estimated)
- New pill shows promise against tough breast cancer Results expected Nov 2026 (estimated)
- New immunotherapy cocktails aim to outsmart resistant ovarian cancer Results expected Dec 2026 (estimated)
- Can talk therapy and symptom tracking ease the trauma of leukemia? Results expected Dec 2026 (estimated)
- Canadian trial matches cancer drugs to gene mutations Results expected Dec 2026 (estimated)
-
Exercise program tested to keep colon cancer at bay
Disease control CompletedThis study tested whether a 3-year physical activity program could help prevent colon cancer from coming back in 889 patients who had surgery and chemotherapy for high-risk stage II or stage III colon cancer. Participants were randomly assigned to either the exercise program plus…
Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Prostate cancer radiation showdown: which treatment wins?
Disease control CompletedThis study compared two types of radiation therapy for men with intermediate-risk prostate cancer: standard image-guided external beam radiation (IGRT) versus IGRT plus a high-dose-rate brachytherapy boost. The goal was to see which treatment works better and what side effects oc…
Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can a lower dose of palbociclib work just as well for advanced breast cancer?
Disease control CompletedThis completed phase 2 trial enrolled 180 women with ER-positive, HER2-negative advanced or metastatic breast cancer. Researchers compared two different dosing schedules of the targeted drug palbociclib (100 mg daily vs. 125 mg for 3 weeks on, 1 week off) combined with standard h…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Chemo-First approach aims to save rectums in early cancer trial
Disease control CompletedThis study tested giving chemotherapy before a less invasive surgery for early rectal cancer. The goal was to see if this approach could allow patients to keep their rectum instead of needing major surgery. 58 people took part, and the treatment was considered successful if at le…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental cocktail targets Hard-to-Treat lymphomas
Disease control CompletedThis early-phase trial tested a combination of four drugs—romidepsin, gemcitabine, dexamethasone, and cisplatin—in 21 people with peripheral T-cell or diffuse large B-cell lymphoma who had already tried other treatments. The main goal was to find a safe dose of romidepsin when ad…
Phase 1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond bett…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Can an Immune-Boosting drug stop lung cancer from returning?
Prevention CompletedThis phase III trial tests whether the immunotherapy drug durvalumab (MEDI4736) can prevent non-small cell lung cancer from returning after patients have surgery and possibly chemotherapy. Participants have completely resected stage IB, II, or IIIA lung cancer and are randomly as…
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Could a simple immunization shield cancer patients from severe COVID-19?
Prevention CompletedThis phase 3 trial tested whether a biologic called IMM-101 could reduce severe respiratory infections, including COVID-19, in cancer patients at higher risk. 195 participants either received three doses of IMM-101 or were simply observed. The goal was to see if the treatment cou…
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Jun 27, 2026 08:07 UTC